Mizuho Maintains Outperform on Harmony Biosciences Hldgs, Raises Price Target to $51

Benzinga Newsdesk www.benzinga.com Positive 93.6%

Neg 0% Neu 0% Pos 93.6%

Mizuho analyst Graig Suvannavejh maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Outperform and raises the price target from $50 to $51.